COMP <GO>
VTRS vs UTHR // EV/EBITDA & P/E VALUATION
Viatris Inc. (NASDAQ) VS. United Therapeutics Corporation (NASDAQ) • 15-METRIC TALLY: VTRS 2
— UTHR 10
■ METRIC PARITY
LAST: $19.04 (-0.86%) • MKT CAP: $22.05B
valuation
—
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
valuation
12.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VTRS VS. UTHR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VTRS | UTHR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.20% | 87.90% | -52.70 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.10% | 20.10% | -28.20 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 12.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.78% | 4.09% | +4.69 | VTRS | /fcf-yield <GO> |
| Operating Margin | -18.70% | 46.90% | -65.60 | UTHR | /operating-margins <GO> |
| Net Profit Margin | -14.60% | 41.90% | -56.50 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 10.60% | -13.60 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.81 | 22.52 | -21.71 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.8 | 66.9 | -1.10 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.95 | +0.20 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 17.8x | +15.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.05B | $25.46B | -$3.40B | UTHR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VTRS REV | UTHR REV | VTRS GROSS % | UTHR GROSS % | VTRS FCF | UTHR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.25B | $3.18B | 35.2% | 87.9% | $1.94B | $1.04B |
| FY 2024 | $14.69B | $2.88B | 38.3% | 89.2% | $1.98B | $1.08B |
| FY 2023 | $15.39B | $2.33B | — | — | $2.21B | $873.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VTRS // BETA 1.15
UTHR // BETA 0.95